Zim Laboratories Ltd

A sharp decline of 8.16% today dragged Zim Laboratories Ltd to a fresh 52-week low of Rs 63, extending its downward trajectory amid broader market weakness and company-specific concerns.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Zim Laboratories Ltd has reached a new 52-week low of Rs.63.48 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance concerns.

Zim Laboratories Ltd has touched a new 52-week low of Rs.64 today, marking a significant decline in its stock price amid a broader bearish trend in the Pharmaceuticals & Biotechnology sector. The stock has been under pressure for the past two days, falling by 4.42% during this period, and continues to trade below all key moving averages.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net profit of ₹4.40 crores for Q3 FY26 (October-December 2025), marking a dramatic turnaround from the ₹0.42 crore loss recorded in Q2 FY26. However, this sequential recovery, whilst impressive at first glance, reveals deeper structural concerns when viewed against year-on-year comparisons and margin pressures that continue to plague the ₹407 crore market capitalisation company.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 05 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into its performance and outlook.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Zim Laboratories Ltd has touched a new 52-week low of Rs.64.1 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics. Despite a modest recovery over the past two days, the stock remains considerably below its previous highs and continues to trail behind sector benchmarks.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 August 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation metrics reflecting ongoing challenges in its financial and operational performance. This shift highlights the company’s current standing amid a backdrop of subdued profitability and persistent negative results.